Science

The Clinical Evidence for Psychedelic-Assisted Psychotherapy

For decades, the dominant model of mental health treatment has rested on two pillars: talk therapy and pharmacology.

For many people, that model works.

For a significant number, it does not.

1 in 3 people with depression do not achieve adequate response with standard antidepressant treatment. (Fava, M. — Journal of Clinical Psychiatry, 2003.) For PTSD, the numbers are similarly sobering. For treatment-resistant conditions, conventional approaches often reach a ceiling — and stay there.

This is not a failure of effort. It is a limitation of tools.

Psychedelic-Assisted Psychotherapy represents a clinically distinct approach — one that works through different mechanisms, on different timescales, with outcomes that a growing body of rigorous research is finding difficult to ignore.

This page explains what the science actually says.

How It Works: The Mechanism

To understand why this approach produces the outcomes it does, it helps to understand what is happening neurologically.

Neuroplasticity and the Default Mode Network

The brain has a default mode network — a set of interconnected regions that are active when the mind is at rest, not focused on a task. In people with depression, PTSD, and anxiety disorders, this network tends toward rigid, repetitive patterns. The same thoughts. The same emotional responses. The same loops.

Psychedelic-Assisted Psychotherapy disrupts that rigidity.

Research from Imperial College London (Carhart-Harris et al., 2017) demonstrated that this therapeutic approach produces measurable increases in neuroplasticity — the brain's capacity to form new connections and reorganise existing ones. It temporarily quiets the default mode network, creating a window during which entrenched patterns become more malleable.

This is not a metaphor. It is a documented neurological event.

The Critical Learning Window

That window does not last indefinitely. The days and weeks following a supervised session represent a period of heightened neuroplasticity — a time during which the brain is measurably more receptive to change.

This is why integration is not optional. It is clinically essential.

What the therapeutic team does during that window — and what the person does with the material that emerged during the session — has a direct effect on outcomes. The research supports this clearly.

What the Research Shows

The clinical evidence for Psychedelic-Assisted Psychotherapy has accumulated across multiple conditions, multiple institutions, and multiple study designs. What follows is a summary of the most significant findings.

Treatment-Resistant Depression

A landmark randomised controlled trial published in The New England Journal of Medicine (Goodwin et al., 2023) found that 29% of participants with treatment-resistant depression achieved remission following a single supervised session — compared to 8% in the control group. Response rates were significantly higher across all measured outcomes.

This was not a small study. It was a Phase IIb trial. 233 participants. Rigorous methodology. Placebo-controlled.

A separate study from Imperial College London (New England Journal of Medicine, 2021) compared this approach directly with a leading conventional antidepressant. Both produced comparable reductions in depressive symptoms. The psychedelic approach showed faster onset and higher rates of sustained response at the six-week mark.

PTSD

Research published in Nature Medicine (Mitchell et al., 2021) — a Phase 3 trial conducted across multiple sites — found that 67% of participants receiving MDMA-assisted psychotherapy no longer met diagnostic criteria for PTSD at the two-month follow-up. In the placebo group, that figure was 32%.

These are not marginal improvements. They represent a clinically meaningful difference in the lives of people who had, in many cases, carried their diagnosis for years.

Anxiety and End-of-Life Distress

A double-blind randomised trial from Johns Hopkins University (Davis et al., 2021) found significant reductions in anxiety and depression symptoms in participants with major depressive disorder, with effects sustained at the 12-month follow-up — a durability that is rare in the pharmacological literature.

Addiction

Research from Yale University and NYU has documented significant reductions in alcohol use disorder and tobacco dependence following supervised psychedelic therapy, with abstinence rates at 12 months substantially exceeding those of standard pharmacological interventions.

Who Is Conducting This Research

The institutions currently leading clinical investigation into Psychedelic-Assisted Psychotherapy include some of the most respected research centres in the world.

Imperial College London — Psychedelic Research Centre, led by Professor Robin Carhart-Harris. Pioneering neuroimaging work documenting brain changes associated with this approach.

Johns Hopkins University — Centre for Psychedelic and Consciousness Research. The most active clinical research programme in the United States, with over 60 ongoing or completed studies.

NYU Langone Health — Ongoing trials in addiction, depression, and eating disorders.

MAPS (Multidisciplinary Association for Psychedelic Studies) — Coordinating Phase 3 clinical trials across multiple countries, with FDA Breakthrough Therapy designation for PTSD treatment.

University of Zurich and University Hospital Basel — European leaders in clinical pharmacology and psychedelic research.

This is not fringe science. It is mainstream clinical research, funded by academic institutions, peer-reviewed, and replicable.

What the Evidence Does — and Does Not — Say

Intellectual honesty requires a note of precision here.

The evidence base for Psychedelic-Assisted Psychotherapy is substantial and growing. It is also, by the standards of established pharmacology, still relatively recent. Most large-scale trials have been conducted in the last decade. Long-term follow-up data — beyond 12 months — is limited for some conditions.

What the evidence clearly supports:

• Rapid and significant reduction in depressive symptoms in treatment-resistant populations.
• Clinically meaningful outcomes in PTSD, including remission in a substantial proportion of participants.
• Durable response rates that compare favourably with standard pharmacological treatment.
• A neurological mechanism — increased neuroplasticity, altered default mode network activity — that is measurable and reproducible.

What remains under investigation:

• Optimal dosing protocols across conditions.
• Long-term durability beyond 12 months for some populations.
• Predictors of response — who benefits most, and why.

At Enthea, we work within what the evidence supports. We do not claim more than the research demonstrates. We do not dismiss what it clearly shows.

What This Means for You

Science is not an argument. It is a foundation.

The reason we cite these studies — with their authors, their institutions, their methodology — is not to impress. It is to give you the information you need to make a considered decision.

You are not being asked to take this on faith.

You are being invited to look at the evidence, ask the questions it raises, and decide whether this is something worth exploring for your specific situation.

If you want to understand how this evidence applies to a particular condition, our treatments section addresses each one individually — with the relevant research cited.

If you want to understand how we translate this science into clinical practice, our approach explains the process in full.

If this resonates, we can talk.

The studies referenced on this page are published in peer-reviewed journals and are available in full through their respective publishers. Enthea Institute does not conduct independent research. We apply evidence-based protocols developed in collaboration with established clinical guidelines.